Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.090
+0.180 (4.60%)
At close: May 8, 2026, 4:00 PM EDT
4.160
+0.070 (1.70%)
After-hours: May 8, 2026, 6:33 PM EDT
Oramed Pharmaceuticals Revenue
In the year 2025, Oramed Pharmaceuticals had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
82.71
Revenue / Employee
$500,000
Employees
4
Market Cap
165.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | -9.00K | -0.33% |
| Dec 31, 2021 | 2.71M | 9.00K | 0.33% |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 52.74M |
| ProQR Therapeutics | 19.19M |
| Kazia Therapeutics | 1.27M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
ORMP News
- 6 weeks ago - Lifeward closes strategic partnership agreement with Oramed - TheFly
- 2 months ago - Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company - GlobeNewsWire
- 4 months ago - Oramed and Lifeward sign strategic transaction - TheFly
- 4 months ago - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - GlobeNewsWire
- 4 months ago - Oramed and Lifeward Announce Strategic Transaction - PRNewsWire
- 4 months ago - Oramed receives $18M payment from Scilex Holdings - TheFly
- 4 months ago - Oramed declares cash dividend payment of 25c per share - TheFly
- 4 months ago - Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - PRNewsWire